Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone.

Trial Profile

Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone.

Completed
Phase of Trial: Phase 0

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Rosiglitazone (Primary) ; Zileuton (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 28 Jul 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Actual initiation date 1 Jul 2011 added as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Trial phase changed from I to 0 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top